Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction

Yuya Matsue; Makoto Suzuki; Sho Torii; Satoshi Yamaguchi; Seiji Fukamizu; Yuichi Ono; Hiroyuki Fujii; Takeshi Kitai; Toshihiko Nishioka; Kaoru Sugi; Yuko Onishi; Makoto Noda; Nobuyuki Kagiyama; Yasuhiro Satoh; Kazuki Yoshida; Steven R. Goldsmith

doi:10.1016/j.cardfail.2016.02.007

Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction

Yuya Matsue, Makoto Suzuki, Sho Torii, Satoshi Yamaguchi, Seiji Fukamizu, Yuichi Ono, Hiroyuki Fujii, Takeshi Kitai, Toshihiko Nishioka, Kaoru Sugi, Yuko Onishi, Makoto Noda, Nobuyuki Kagiyama, Yasuhiro Satoh, Kazuki Yoshida, Steven R. Goldsmith

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

Background More efficacious and/or safer decongestive therapy is clearly needed in acute heart failure (AHF) patients complicated by renal dysfunction. We tested the hypothesis that adding tolvaptan, an oral vasopressin-2 receptor antagonist, to conventional therapy with loop diuretics would be more effective treatment in this population. Methods and Results A multicenter, open-label, randomized control trial was performed, and 217 AHF patients with renal dysfunction (estimated glomerular filtration rate 15–60 mL • min⁻¹ • 1.73 m⁻²) were randomized 1:1 to treatment with tolvaptan (n = 108) or conventional treatment (n = 109). The primary end point was 48-hour urine volume. The tolvaptan group showed more diuresis than the conventional treatment group (6464.4 vs 4999.2 mL; P < .001) despite significantly lower amounts of loop diuretic use (80 mg vs 120 mg; P < .001). Dyspnea relief was achieved significantly more frequently in the tolvaptan group at all time points within 48 hours except 6 hours after enrollment. The rate of worsening of renal function (≥0.3 mg/dL increase from baseline) was similar between the tolvaptan and conventional treatment groups (24.1% vs 27.8%, respectively; P = .642). Conclusions Adding tolvaptan to conventional treatment achieved more diuresis and relieved dyspnea symptoms in AHF patients with renal dysfunction. Clinical Trial Registration URL: http://www.umin.ac.jp/ctr/index/htm/

Original language	English (US)
Pages (from-to)	423-432
Number of pages	10
Journal	Journal of cardiac failure
Volume	22
Issue number	6
DOIs	https://doi.org/10.1016/j.cardfail.2016.02.007
State	Published - Jun 1 2016

Bibliographical note

Funding Information:
Funding/Support: The AQUAMARINE study was funded by Japan Heart Foundation Multicenter Study Grant.

Funding Information:
Conflict of Interest Disclosures: Dr Yuya Matsue received an honorarium from Otsuka Pharmaceutical Co. Dr Makoto Suzuki received lecture honoraria from Otsuka Pharmaceutical Co, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Medtronic Japan Co, Boston Scientific Japan Co, and Fukuda Denshi. Dr Kazuki Yoshida receives tuition support jointly from the Japan Student Services Organization and Harvard T. H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). Dr Kaoru Sugi received scholership fund from Daiichi-Sankyo Pharmaceutical and lecture honoraria from Bayer. Dr Steven R. Goldsmith received consulting fees, speaking fees, and research support from Otsuka USA and Otsuka-Japan. The other authors have nothing to disclose.

Publisher Copyright:
© 2016 Elsevier Inc.

Keywords

Vasopressin antagonist
acute heart failure
renal function

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.cardfail.2016.02.007

OpenUrl availability

Full text

Cite this

Matsue, Y., Suzuki, M., Torii, S., Yamaguchi, S., Fukamizu, S., Ono, Y., Fujii, H., Kitai, T., Nishioka, T., Sugi, K., Onishi, Y., Noda, M., Kagiyama, N., Satoh, Y., Yoshida, K., & Goldsmith, S. R. (2016). Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. Journal of cardiac failure, 22(6), 423-432. https://doi.org/10.1016/j.cardfail.2016.02.007

Matsue, Y, Suzuki, M, Torii, S, Yamaguchi, S, Fukamizu, S, Ono, Y, Fujii, H, Kitai, T, Nishioka, T, Sugi, K, Onishi, Y, Noda, M, Kagiyama, N, Satoh, Y, Yoshida, K & Goldsmith, SR 2016, 'Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction', Journal of cardiac failure, vol. 22, no. 6, pp. 423-432. https://doi.org/10.1016/j.cardfail.2016.02.007

@article{db4d419397ac4c459fdbe1a5034925e4,

title = "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction",

abstract = "Background More efficacious and/or safer decongestive therapy is clearly needed in acute heart failure (AHF) patients complicated by renal dysfunction. We tested the hypothesis that adding tolvaptan, an oral vasopressin-2 receptor antagonist, to conventional therapy with loop diuretics would be more effective treatment in this population. Methods and Results A multicenter, open-label, randomized control trial was performed, and 217 AHF patients with renal dysfunction (estimated glomerular filtration rate 15–60 mL • min−1 • 1.73 m−2) were randomized 1:1 to treatment with tolvaptan (n = 108) or conventional treatment (n = 109). The primary end point was 48-hour urine volume. The tolvaptan group showed more diuresis than the conventional treatment group (6464.4 vs 4999.2 mL; P < .001) despite significantly lower amounts of loop diuretic use (80 mg vs 120 mg; P < .001). Dyspnea relief was achieved significantly more frequently in the tolvaptan group at all time points within 48 hours except 6 hours after enrollment. The rate of worsening of renal function (≥0.3 mg/dL increase from baseline) was similar between the tolvaptan and conventional treatment groups (24.1% vs 27.8%, respectively; P = .642). Conclusions Adding tolvaptan to conventional treatment achieved more diuresis and relieved dyspnea symptoms in AHF patients with renal dysfunction. Clinical Trial Registration URL: http://www.umin.ac.jp/ctr/index/htm/",

keywords = "Vasopressin antagonist, acute heart failure, renal function",

author = "Yuya Matsue and Makoto Suzuki and Sho Torii and Satoshi Yamaguchi and Seiji Fukamizu and Yuichi Ono and Hiroyuki Fujii and Takeshi Kitai and Toshihiko Nishioka and Kaoru Sugi and Yuko Onishi and Makoto Noda and Nobuyuki Kagiyama and Yasuhiro Satoh and Kazuki Yoshida and Goldsmith, {Steven R.}",

note = "Funding Information: Funding/Support: The AQUAMARINE study was funded by Japan Heart Foundation Multicenter Study Grant. Funding Information: Conflict of Interest Disclosures: Dr Yuya Matsue received an honorarium from Otsuka Pharmaceutical Co. Dr Makoto Suzuki received lecture honoraria from Otsuka Pharmaceutical Co, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Medtronic Japan Co, Boston Scientific Japan Co, and Fukuda Denshi. Dr Kazuki Yoshida receives tuition support jointly from the Japan Student Services Organization and Harvard T. H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). Dr Kaoru Sugi received scholership fund from Daiichi-Sankyo Pharmaceutical and lecture honoraria from Bayer. Dr Steven R. Goldsmith received consulting fees, speaking fees, and research support from Otsuka USA and Otsuka-Japan. The other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.cardfail.2016.02.007",

language = "English (US)",

volume = "22",

pages = "423--432",

journal = "Journal of cardiac failure",

issn = "1071-9164",

publisher = "Churchill Livingstone",

number = "6",

}

TY - JOUR

T1 - Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction

AU - Matsue, Yuya

AU - Suzuki, Makoto

AU - Torii, Sho

AU - Yamaguchi, Satoshi

AU - Fukamizu, Seiji

AU - Ono, Yuichi

AU - Fujii, Hiroyuki

AU - Kitai, Takeshi

AU - Nishioka, Toshihiko

AU - Sugi, Kaoru

AU - Onishi, Yuko

AU - Noda, Makoto

AU - Kagiyama, Nobuyuki

AU - Satoh, Yasuhiro

AU - Yoshida, Kazuki

AU - Goldsmith, Steven R.

N1 - Funding Information: Funding/Support: The AQUAMARINE study was funded by Japan Heart Foundation Multicenter Study Grant. Funding Information: Conflict of Interest Disclosures: Dr Yuya Matsue received an honorarium from Otsuka Pharmaceutical Co. Dr Makoto Suzuki received lecture honoraria from Otsuka Pharmaceutical Co, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Medtronic Japan Co, Boston Scientific Japan Co, and Fukuda Denshi. Dr Kazuki Yoshida receives tuition support jointly from the Japan Student Services Organization and Harvard T. H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). Dr Kaoru Sugi received scholership fund from Daiichi-Sankyo Pharmaceutical and lecture honoraria from Bayer. Dr Steven R. Goldsmith received consulting fees, speaking fees, and research support from Otsuka USA and Otsuka-Japan. The other authors have nothing to disclose. Publisher Copyright: © 2016 Elsevier Inc.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background More efficacious and/or safer decongestive therapy is clearly needed in acute heart failure (AHF) patients complicated by renal dysfunction. We tested the hypothesis that adding tolvaptan, an oral vasopressin-2 receptor antagonist, to conventional therapy with loop diuretics would be more effective treatment in this population. Methods and Results A multicenter, open-label, randomized control trial was performed, and 217 AHF patients with renal dysfunction (estimated glomerular filtration rate 15–60 mL • min−1 • 1.73 m−2) were randomized 1:1 to treatment with tolvaptan (n = 108) or conventional treatment (n = 109). The primary end point was 48-hour urine volume. The tolvaptan group showed more diuresis than the conventional treatment group (6464.4 vs 4999.2 mL; P < .001) despite significantly lower amounts of loop diuretic use (80 mg vs 120 mg; P < .001). Dyspnea relief was achieved significantly more frequently in the tolvaptan group at all time points within 48 hours except 6 hours after enrollment. The rate of worsening of renal function (≥0.3 mg/dL increase from baseline) was similar between the tolvaptan and conventional treatment groups (24.1% vs 27.8%, respectively; P = .642). Conclusions Adding tolvaptan to conventional treatment achieved more diuresis and relieved dyspnea symptoms in AHF patients with renal dysfunction. Clinical Trial Registration URL: http://www.umin.ac.jp/ctr/index/htm/

AB - Background More efficacious and/or safer decongestive therapy is clearly needed in acute heart failure (AHF) patients complicated by renal dysfunction. We tested the hypothesis that adding tolvaptan, an oral vasopressin-2 receptor antagonist, to conventional therapy with loop diuretics would be more effective treatment in this population. Methods and Results A multicenter, open-label, randomized control trial was performed, and 217 AHF patients with renal dysfunction (estimated glomerular filtration rate 15–60 mL • min−1 • 1.73 m−2) were randomized 1:1 to treatment with tolvaptan (n = 108) or conventional treatment (n = 109). The primary end point was 48-hour urine volume. The tolvaptan group showed more diuresis than the conventional treatment group (6464.4 vs 4999.2 mL; P < .001) despite significantly lower amounts of loop diuretic use (80 mg vs 120 mg; P < .001). Dyspnea relief was achieved significantly more frequently in the tolvaptan group at all time points within 48 hours except 6 hours after enrollment. The rate of worsening of renal function (≥0.3 mg/dL increase from baseline) was similar between the tolvaptan and conventional treatment groups (24.1% vs 27.8%, respectively; P = .642). Conclusions Adding tolvaptan to conventional treatment achieved more diuresis and relieved dyspnea symptoms in AHF patients with renal dysfunction. Clinical Trial Registration URL: http://www.umin.ac.jp/ctr/index/htm/

KW - Vasopressin antagonist

KW - acute heart failure

KW - renal function

UR - http://www.scopus.com/inward/record.url?scp=84962124728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962124728&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2016.02.007

DO - 10.1016/j.cardfail.2016.02.007

M3 - Article

C2 - 26915749

AN - SCOPUS:84962124728

SN - 1071-9164

VL - 22

SP - 423

EP - 432

JO - Journal of cardiac failure

JF - Journal of cardiac failure

IS - 6

ER -

Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this